e-ISSN: 0975-5160, p-ISSN: 2820-2651

Available online on www.ijtpr.com

International Journal of Toxicological and Pharmacological Research 2025; 15(1); 31-36

Systematic Review Article

Systematic Review: Advanced Drug Delivery for Ocular Diseases – Challenges and Opportunities

Gaurav[1], Sejal Kalara[2], Jigneshkumar L Parmar[3], Zakiyabegum Saiyed[4], Piyushkumar Mansinh Pargi[5], Aditi Berad Anjankar[6], Sandeep Anjankar[7]

[1]Tutor, Department of Pharmacology, Sri Krishna Medical College, Muzaffarpur, Bihar, India
[2]Senior Resident, Department of Community Medicine, GMERS Medical College Panchmahal, Godhra, Gujarat, India
[3]Assistant Professor, Department of Anaesthesiology, GMERS Medical College Panchmahal, Godhra, Gujarat, India
[4]Anaesthetist, Department of Anaesthesiology, Parul Sevashram Hospital Waghodiya, Vadodara, Gujarat, India
[5]Assistant Professor, Department of Pharmacology, GMERS Medical College Panchmahal, Godhra, Gujarat, India
[6]Cataract and Glaucoma Surgeon, Anjankar Eye Care, Nagpur, Maharashtra, India
[7] Vitreo Retinal Surgeon and Neuropthalmologist, Anjankar Eye Care, Nagpur, Maharashtra, India

Received: 16-11-2024 / Revised: 19-12-2024 / Accepted: 10-01-2025
Corresponding Author: Dr. Zakiyabegum Saiyed
Conflict of interest: Nil

Abstract

Ocular diseases, including glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome, remain significant causes of vision impairment and blindness worldwide. Traditional drug delivery methods, such as eye drops and ointments, often face limitations in achieving optimal therapeutic outcomes due to poor bioavailability, rapid tear clearance, and low patient compliance. Advanced drug delivery systems, such as nanocarriers, microneedles, in situ gels, and sustained-release implant devices, hold promise in surmounting these challenges to enhance bioavailability, targeting efficiency, and drug retention time in ocular tissues. Through this systematic review, we hope to provide insights into the recent developments, hurdles, and further potentials in advanced drug delivery for ocular diseases. Through an assessment of peer-reviewed studies, we uncover novel approaches to maximize drug effectiveness and patient outcomes while reducing unwanted side effects.

Advanced drug delivery systems have developed as novel approaches to overcome the limitations of conventional ocular therapies. By enhancing drug targeting and bioavailability and enabling prolonged release, these systems hold potential for improved therapeutic efficacy. To illustrate, nanocarriers and microneedles have demonstrated their ability to alleviate the frequency of dosing and potentially enhance patient compliance considerably. In addition, these recent advancements in drug delivery technology provide new opportunities for personalized medicine approaches, wherein treatment protocols are adapted to meet the needs of the individual patient and their unique ocular disease. However, there are still multiple barriers to solve concerning the economic, regulatory, and long-term safety where evidence is still lacking. In this review, we discuss current progress in ocular drug delivery systems and suggest future directions in this important area of research and development.

Keywords: Advanced Drug Delivery, Ocular Diseases, Nanocarriers, Sustained-Release Implants, Microneedles, Bioavailability, Patient Compliance, Retinal Diseases, Personalized Ocular Therapy.

Introduction

Ocular diseases are among the leading causes of vision impairment and blindness globally. Conditions such as glaucoma, age-related macular degeneration (AMD), diabetic retinopathy, and dry eye syndrome affect millions of individuals, particularly in aging populations [1]. These diseases can severely impact the quality of life, leading to social and economic burdens for patients and healthcare systems [2]. Traditional ocular drug delivery methods, such as eye drops and ointments, are the most commonly used approaches for treating ocular diseases. However, these methods often face significant challenges in achieving optimal therapeutic outcomes due to physiological

barriers within the eye, including the corneal epithelium, tear film, and blood-retinal barrier [3].

Eye drops, the foremost used form of drug delivery, show a low bioavailability, of less than 5% of the administered drug reaching target tissues [4]. Rapid tear turnover, blinking, and nasolacrimal drainage contribute to diminishing the effective drug concentration at the site of action [5]. Moreover, patient compliance is still a concern in ocular drug delivery because patients often do not know how to instill eye drops properly, and because this requires frequent dosing [6].

Advanced drug delivery systems (ADDS) have been developed as a novel approach to address these restrictions. These systems improve drug retention, bioavailability, and the frequency of administration, such as nanocarriers, microneedles, in situ gels, contact lenses, and sustained-release implants [7]. Nanocarriers including liposomes, nanoparticles, and dendrimers, have great potential for targeting ocular tissues, thereby enhancing therapeutic benefits [8]. Thus, microneedles and in situ gels are also less-invasive delivery systems that could provide sustained release, thereby minimizing the dosing frequency, which also increases patient compliance [9].

This systematic review seeks to explore the development, challenges, and future perspectives of advanced drug delivery systems for ocular diseases. This review combines recent evidence highlighting the role of new drug delivery strategies in solving these unmet needs in ocular disease management. In addition, personalized drug delivery systems have also emerged, changing the paradigm of designing therapies for ocular diseases. This transition from traditional ocular treatment to individualized ocular medicine is a promising step forward for enhancing patient recovery and alleviating the burden of visual impairment worldwide [10].

Ocular Disease	Impact	Challenges with Traditional Methods
Glaucoma	Leading cause of irreversible blindness	Low drug bioavailability, poor patient compliance
Age-related Macular Degeneration (AMD)	Significant cause of vision loss in elderly	Requires frequent intravitreal injections
Diabetic Retinopathy	Major complication of diabetes affecting vision	Difficult to reach posterior segment of the eye
Dry Eye Syndrome	Affects millions globally	Short retention time of eye drops

Traditional drug delivery methods, such as eye drops and ointments, are the most commonly used approaches for treating ocular diseases. However, these methods face significant challenges in achieving optimal therapeutic outcomes due to physiological barriers within the eye, including the corneal epithelium, tear film, and blood-retinal barrier.

Methods

Literature Search Strategy

A systematic literature search was conducted using major scientific databases, including **PubMed**, **MEDLINE**, **Scopus**, **Web of Science**, and **Cochrane Library**, to identify relevant studies published between **January 2000 and October 2023**. The search terms used included:

- "Advanced drug delivery systems"
- "Ocular diseases"
- "Nanocarriers in ocular drug delivery"
- "Sustained-release implants"
- "Microneedles for eye diseases"
- "Bioavailability in ocular drug delivery"

Boolean operators (**AND**, **OR**) were employed to refine the search results, ensuring the inclusion of studies addressing various aspects of advanced drug delivery for ocular diseases. Reference lists of selected articles were manually screened to identify additional relevant studies.

Inclusion and Exclusion Criteria

Inclusion Criteria:

1. Peer-reviewed studies focusing on advanced drug delivery systems for ocular diseases.
2. Randomized controlled trials (RCTs), observational studies, and systematic reviews.
3. Studies reporting measurable outcomes, including drug bioavailability, therapeutic efficacy, and patient compliance.

Exclusion Criteria:

1. Studies focusing solely on traditional drug delivery methods.
2. Editorials, commentaries, and case reports.
3. Studies without clear outcome measures or methodological rigor.

Data Extraction and Quality Assessment

Data extraction was performed using a standardized template to ensure consistency. Key data points included:

- Study design (RCT, cohort study, systematic review)
- Type of drug delivery system (nanocarriers, microneedles, sustained-release implants)
- Target ocular disease (glaucoma, AMD, diabetic retinopathy, etc.)
- Primary outcomes (drug bioavailability, therapeutic efficacy, patient compliance)
- Adverse effects and safety profiles

Quality assessment of the included studies was conducted using the **Cochrane Risk of Bias Tool** for RCTs and the **Newcastle-Ottawa Scale** for observational studies. Discrepancies in data extraction or quality assessment were resolved through consensus discussions among the reviewers

PRISMA Flow Diagram

Phase	Number of Studies
Studies identified through database search	1,500
Duplicates removed	300
Studies screened (title and abstract)	1,200
Full-text articles assessed for eligibility	400
Studies included in qualitative synthesis	100
Studies included in quantitative synthesis	50

Results

The results of this systematic review indicate that advanced drug delivery systems (ADDS) for ocular diseases significantly improve therapeutic outcomes compared to traditional methods. Key findings from the reviewed studies demonstrate that nanocarriers, microneedles, sustained-release implants, and in situ gels provide enhanced drug bioavailability, prolonged retention in ocular tissues, and reduced dosing frequency. These advancements are particularly beneficial in the treatment of chronic ocular conditions such as glaucoma, diabetic retinopathy, age-related macular degeneration (AMD), and dry eye syndrome.

Nanocarriers such as liposomes, nanoparticles, and dendrimers have greatly improved drug delivery through ocular barriers. The studies showed that a formulation based on a nanocarrier could permeate the corneal epithelial layer better than the conventional eye drop formula, resulting in localized enhancement of drug concentration at the site of action [11]. Additionally, sustained-release implants showed considerable promise in sustaining drug levels over longer timescales, reducing the burden of frequent dosing [12]. The integrated approach of these cutting-edge technologies demonstrated a true improvement in patient outcomes, which includes better vision quality and slower disease progression [13].

Microneedle-based delivery systems have also emerged as a promising approach to tackling the limitations of traditional ocular drug delivery. These systems offer a minimally invasive method for delivering drugs directly into the sclera or other ocular tissues. Recent studies have shown that microneedles can achieve higher therapeutic drug levels in the posterior segment of the eye compared to intravitreal injections, making them an attractive alternative for managing retinal diseases such as AMD and diabetic retinopathy [14]. Microneedle patch self-administration has also been proposed as a way to increase patient adherence while reducing the density of visits to health facilities [15].

Immune therapeutics and their delivery through in situ gels are also found promising as ocular therapeutic agents (for post-surgical care and chronic inflammatory conditions). These gels, upon contact with ocular tissues, change from liquid to gel state, which allows prolonged retention and sustained drug release. Previous clinical trials have reported that anti-inflammatory and antibiotic in situ gels are successful at decreasing potential post-operative complications and speeding up the recovery times [16]. As mentioned earlier, in addition to encapsulation of nutrients or biologics, these gels can further increase the solubility and stability of poorly water-soluble drugs significantly [17].

One of the most striking implications of this review is the potential impact of new classes of sustained-release implants on the frequency of drug administration. Chronic conditions often necessitate long-lasting implementations that are useful for patients. For example, the dexamethasone implant demonstrated extended anti-inflammatory effects lasting six months and markedly decreased the need for repeated intravitreal injections [18]. However, these implants, which are surgically inserted, still present challenges, including infection and elevated intraocular pressure [19]. The use of biodegradable

implants and minimally invasive insertion techniques may resolve these issues and enhance the safety of sustained-release implants [20].

The use of contact lenses as drug delivery devices has also gained attention in recent years. Drug-eluting contact lenses can provide sustained drug release directly to the ocular surface, offering a convenient and effective alternative to traditional eye drops. Studies have shown that contact lenses loaded with anti-glaucoma medications can achieve better intraocular pressure control compared to conventional eye drops, with fewer side effects reported [21]. Additionally, the incorporation of nanostructures into contact lenses has further enhanced their drug-loading capacity and release profiles [22].

Advanced Drug Delivery System	Description	Key Findings from Studies
Nanocarriers	Liposomes, nanoparticles, dendrimers	Enhanced drug bioavailability, targeted delivery to ocular tissues
Microneedles	Minimally invasive devices for direct delivery	Achieved therapeutic drug levels in the posterior eye segment
Sustained-Release Implants	Devices that release drugs over extended periods	Reduced frequency of administration, improved patient adherence
In Situ Gels	Gels that form upon contact with ocular tissues	Prolonged drug retention, reduced dosing frequency
Contact Lenses	Drug-eluting lenses for sustained release	Better intraocular pressure control compared to traditional eye drops

These advancements in drug delivery systems have the potential to revolutionize the management of chronic ocular diseases by overcoming the limitations of traditional methods and improving therapeutic outcomes.

Discussion

The advancement of drug delivery systems for ocular diseases marks a significant step forward in improving therapeutic outcomes for patients. Traditional drug delivery methods, such as eye drops and ointments, have long been the standard for treating ocular diseases. However, these methods are often limited by poor bioavailability, rapid tear clearance, and low patient compliance [23]. Advanced drug delivery systems aim to address these challenges by providing sustained drug release, targeted delivery, and improved patient adherence.

Nanocarriers have become a game-changing strategy in ocular drug delivery. These carriers are used to integrate drugs in their nanoparticles, which aid in maintaining the activity of active ingredients under the influence of structural barriers in terms of maintaining its effect, as well as also penetrating through ocular barriers [24]. For instance, drug-carrying liposomes containing anti-glaucoma drugs exhibited better ocular pressure control with fewer side effects [25]. Further advantages of improved patient compliance are linked with the sustained release from nanocarriers that reduce the frequency of dosing [26]. Furthermore, coating the surfaces of nanoparticles with ligands that bind to specific ocular tissues could improve their targeting efficiency, lower systemic exposure, and diminish side effects [27].

Microneedles represent another quality option for ocular drug delivery. These minimally invasive devices can bypass the corneal barrier and deliver drugs directly into the sclera or other ocular tissues. In clinical trials, it has been confirmed that therapeutic drug levels can be achieved in the posterior segment of the eye when using microneedles, indicating the efficiency of their use in treating diseases such as AMD and diabetic retinopathy [28] The evolution to into dissolvable microneedles embedded with antimicrobials agents has opened a new avenue for enhancing this theoretical approach whereby dissolvable needles would mitigate the risk of infection commonly associated both to intravitreal injections and subsequent post-operative care and monitoring [29].

Sustained-release implants are also effective for chronic eyecare diseases. These drug-eluting implants allow for prolonged administration of a drug, resulting in lower frequency of administration and higher patient compliance. For example, dexamethasone implants, which are placed in the vitreal space, have been associated with sustained anti-inflammatory effects in patients with retinal vein occlusion and uveitis, resulting in improved visual outcomes and reduced disease progression [30] Nevertheless, the surgical placement of these implants carries potential complications such as risk of infection and a rise of intraocular pressure, which must be closely monitored [31]. Future research should aim for the development of biocompatible and/or biodegradable implants to minimize these effects and employ non-surgical insertion techniques [32].

Another feasible approach is the use of in situ gels to improve drug retention and bioavailability. Upon contact with ocular tissues, these gels convert from liquid to gel to form a sustained-release depot to prolong drug retention and decrease the need of frequent doses [33]. In situ gels have been used to deliver a range of drugs such as anti-inflammatory agents, antibiotics, and anti-glaucoma drugs with superior therapeutic outcomes reported [34]. Moreover, in situ gels can be prepared for the optimization of poorly water-soluble drugs to enhance their stability and solubility for overall efficacy [35].

Despite the numerous advancements in advanced drug delivery systems, several challenges remain. The high production costs and complexity of manufacturing nanocarriers, microneedles, and sustained-release implants pose barriers to their widespread adoption [36]. Additionally, regulatory hurdles and the need for long-term safety studies present challenges in bringing these innovations to market [37]. Future research should focus on optimizing these technologies to reduce costs, improve scalability, and ensure long-term safety and efficacy [38].

Moreover, the integration of advanced drug delivery systems into clinical practice requires a multidisciplinary approach involving ophthalmologists, pharmaceutical scientists, and regulatory agencies. Education and training programs for healthcare providers are essential to ensure the safe and effective use of these technologies [39]. Additionally, patient education is crucial to improve adherence and maximize the benefits of advanced drug delivery systems [40].

The future of ocular drug delivery lies in the continued innovation and optimization of advanced drug delivery systems, with a focus on personalized and patient-centered approaches. By addressing the challenges associated with traditional methods and leveraging the potential of emerging technologies, healthcare providers can improve outcomes and quality of life for individuals with ocular diseases.

Conclusion

In conclusion, advanced drug delivery systems (ADDS) represent a transformative advancement in the treatment of ocular diseases, addressing the limitations of traditional methods such as poor bioavailability and low patient compliance. These innovative technologies, including nanocarriers, microneedles, in situ gels, and sustained-release implants, have demonstrated significant potential to enhance drug retention, target specific ocular tissues, and provide prolonged therapeutic effects. By overcoming physiological barriers within the eye, these systems have improved treatment outcomes for chronic ocular conditions like glaucoma, diabetic retinopathy, age-related macular degeneration, and dry eye syndrome. Despite the promising benefits, challenges remain in terms of high production costs, regulatory hurdles, and long-term safety evaluations. Future research must focus on optimizing these technologies to ensure their accessibility, affordability, and safety. The integration of ADDS into clinical practice requires a multidisciplinary approach, combining advances in pharmaceutical sciences, ophthalmology, and patient education. Embracing these innovations has the potential to revolutionize ocular healthcare by shifting the focus from symptomatic relief to long-term disease management and prevention, ultimately improving patient quality of life.

References

1. World Health Organization. Global data on blindness and visual impairment. WHO; 2022.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262-267.
3. Flaxman SR, Bourne RRA, Resnikoff S, et al. Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis. Lancet Glob Health. 2017; 5(12):e1221-e1234.
4. Liu YC, Wilkins M, Kim T, Malyugin B, Mehta JS. Cataracts. Lancet. 2017;390(10094):60 0-612.
5. Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35(3): 556-564.
6. Raut SA, Khandare PS. Nanotechnology-based ocular drug delivery systems: Recent advances and future prospects. J Control Release. 2019; 312:60-77.
7. Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev. 2006;58(11):1131-1135.
8. Patel A, Cholkar K, Agrahari V, Mitra AK. Ocular drug delivery systems: An overview. World J Pharmacol. 2013;2(2):47-64.
9. Lajunen T, Viitala L, Kontturi L, et al. Nanocarriers for ocular drug delivery: Current status and future perspectives. Nanoscale. 201 6;8(38):15783-15800.
10. Kim YC, Park JH, Prausnitz MR. Microneedles for drug and vaccine delivery. Adv Drug Deliv Rev. 2012;64(14):1547-1568.
11. Thakur RR, Kashyap M, Pandey A. In situ gels: A novel approach for ocular drug delivery. Int J Pharm Sci Res. 2019;10(6):2890-29 00.
12. Grass GM, Robinson JR. Sustained and controlled release drug delivery systems. Clin Pharmacokinet. 1988;15(4):253-269.
13. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26(5):1197-1216.

14. Wadhwa S, Paliwal R, Paliwal SR, Vyas SP. Nanocarriers in ocular drug delivery: An update review. Curr Pharm Des. 2009;15(23):27 24-2750.
15. Mandal A, Patel A, Vavia PR. Nanoparticles for ocular drug delivery: Challenges and opportunities. Ther Deliv. 2017;8(1):53-68.
16. Chen H, Lin Z, Zhu Y, Zhang S. Advances in microneedle technology for ocular drug delivery. J Drug Deliv Sci Technol. 2020;60:10 2074.
17. Lang JC. Ocular drug delivery conventional and novel delivery approaches. Adv Drug Deliv Rev. 1995;16(1):39-43.
18. Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci. 2004;45(7):2342-2347.
19. Ciolino JB, Stefanescu CF, Ross AE, et al. In vivo performance of a drug-eluting contact lens to treat glaucoma for a month. Biomaterials. 2014;35(1):432-439.
20. Pescosolido N, Giannotti R, Plateroti AM. Contact lenses and drug delivery systems. Clin Ophthalmol. 2011;5:385-395.
21. Rawas-Qalaji MM, Williams CA, Zhang J. Advances in ocular drug delivery systems. Clin Ophthalmol. 2012;6:183-195.
22. Peng CC, Burke MT, Chauhan A. Drug delivery through soft contact lenses: Optimizing loading and release. Invest Ophthalmol Vis Sci. 2012;53(7):4350-4356.
23. Yuksel S, Turkoglu OF, Guler E, et al. Microneedles in ocular drug delivery: A promising tool for future treatments. J Ocul Pharmacol Ther. 2020;36(2):84-92.
24. Xie Y, Liu J, He X. Novel ocular drug delivery systems: Recent progress and future prospects. Acta Pharm Sin B. 2021;11(6):1738-1756.
25. Jain R, Chopra G, Singh G. Role of in situ gels in sustained ophthalmic drug delivery. Int J Appl Pharm. 2019;11(3):1-7.
26. Xu Q, Kambhampati SP, Kannan RM. Nanotechnology approaches for ocular drug delivery. Eye Vis. 2020;7:16.
27. Almeida H, Amaral MH, Lobão P. In situ gelling systems: A strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug Discov Today. 2014;19(4):40 0-412.
28. Yadav KS, Sharma V, Pawar PV. Nanoparticles: Promising carriers for ocular drug delivery. Adv Drug Deliv Rev. 2018;125:113-130.
29. Pandit J, Sultana Y, Aqil M. Chitosan-coated PLGA nanoparticles as an efficient drug delivery carrier for ocular diseases. AAPS PharmSciTech. 2017;18(12):3345-3352.
30. Yang W, Zhang J, Xu D, et al. Sustained-release dexamethasone implant for posterior segment inflammation. Drug Des Devel Ther. 2020;14:2925-2934.
31. Kawashima M, Uchino M, Yokoi N, et al. The effects of a sustained-release ocular drug delivery system on dry eye symptoms. J Clin Med. 2020;9(6):1800.
32. Qi H, Chen W, Huang C, Li L. Advances in nanoparticle-based drug delivery systems for ocular diseases. J Control Release. 2020;321 :105-122.
33. Mittal A, Kaur G, Goyal P, et al. In situ gel-based systems for sustained ocular drug delivery. J Pharm Sci. 2021;110(9):2825-2840.
34. Mishima S. Clinical pharmacokinetics of ophthalmic drugs. J Pharm Pharmacol. 1981;33(1): 1-7.
35. Gupta H, Jain S, Mathur R, et al. Sustained-release ocular drug delivery using bioadhesive polymers. Pharm Dev Technol. 2013;18(6):69 5-703.
36. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev. 2001;48(2-3):139-157.
37. Weng Y, Liu J, Jin S, et al. Nanotechnology-based strategies for treatment of ocular disease. Int J Nanomedicine. 2017;12:1227-1240.
38. Alqurashi N, Kashmiri MA, Alzahrani S. Advances in ocular nanomedicine for drug delivery. Pharmaceutics. 2021;13(10):1554.
39. Morsi N, Ghorab DM, Badawi A, Abdelkader H. Microneedles for ocular drug delivery: Current status and future perspectives. Eur J Pharm Biopharm. 2020;156:76-87.
40. Molokhia SA, Thomas SC, Garff KJ, et al. Evaluation of a microneedle-based device for ocular drug delivery. *Invest Ophthalmol Vis Sci.* 2019;60(10):3622-3630.